Acquisition of Apexigen - Additional Information (Details) - USD ($)		12 Months Ended
	Aug. 23, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Right to receive shares conversion	0.1725
Deferred tax liability, net	$ (2,164,000)
Apexigen, Inc.
Business Acquisition [Line Items]
Stock issued	4,344,435
Deferred tax liability, net	$ (2,200,000)
Issuance costs, incurred		$ 0
General and Administrative
Business Acquisition [Line Items]
Transaction related costs, incurred		$ 1,700,000